The Innovator IBD® 50 ETF (FFTY)

  • A one-stop ETF to invest in the Top 50 growth stocks as selected by IBD
  • Conviction weighted – higher percentage in highest ranked stocks
  • Actively managed
  • Driven by specific fundamental and technical indicators


General Information


The Net Expense Ratio shown for the Innovator IBD® 50 ETF represents a contractual fee waiver in effect through March 30, 2018. The Gross Expense Ratio as of the most recent prospectus (3/30/17) is 1.13%.



The Innovator IBD® 50 ETF is a natural progression of what Investor's Business Daily (IBD) started 30 years ago when its Investing System began to take shape.


IBD 50

The IBD® 50 is the signature standard among Investor's Business Daily's investing tools. As a general rule, IBD® 50 companies are generating outstanding profit growth, big sales increases, wide profit margins and a high return on equity.

The fundamental and technical indicators that combine to drive the IBD® 50 are based on research IBD’s William J. O'Neil began in the 1960's and which continues today. Using data going back to the 1880s, the approach looks for factors which have occurred over and over in top-performing companies:

  • Current earnings increasing quarter-over-quarter
  • Annual earnings increasing year-over-year
  • New product/service/management providing catalyst
  • Stock price moves supported with increasing volume
  • Leading stock in a leading industry
  • Institutional ownership by mutual funds increasing

The IBD® 50 shows no bias toward any industry and stocks selection is not subjective. Ongoing analysis is designed to retain true leaders and replace names when price/volume movement or withering fundamentals demands it. It is this ability to dispassionately refresh itself that is elemental to the targeting of long-term outperformance.


Investor's Business Daily

Founded by O'Neil in 1984, Investor's Business Daily (IBD) is a leading financial news and research organization.

Recognized for its cutting-edge market research, IBD is well regarded for both its national publication as well as its website, Today IBD products are used by leading money managers as well as 200,000 investors.


Fund holdings are subject to change at any time and should not be considered a recommendation to buy or sell any security.






*Fund Inception Date: 4/9/2015

Net Expense Ratio = 0.80%
Gross Expense Ratio = 1.13%

Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Short term performance is not a good indication of the fund's future performance, and an investment should not be made based solely on returns.

  Fact Sheet Summary Prospectus Prospectus SAI Annual Report Semi-Annual Report XBRL
Innovator IBD® 50 ETF Download Download Download Download Download Download Download


View historic premium/discounts



Shareholders may pay more than the net asset value per share (“NAV”) when they buy Fund shares and receive less than NAV when they sell those shares, because shares are bought and sold at current market prices. The data presented represents past performance and cannot be used to predict future results.

The Fund may trade at a premium or discount to NAV. (Premium - The amount the Fund is trading above the reported NAV expressed as a percentage of the NAV. Discount - The amount the Fund is trading below the reported NAV expressed as a percentage of NAV). Shares of the Fund trade based on market prices rather than the Fund's NAV.

Consequently, shares of the Fund may trade at a price greater than (premium) or less than (discount) the Fund's NAV. The above chart presents information for the period indicated about how often the most recent market closing price for shares of the Fund reflected a premium or discount to the Fund's NAV for each trading day and the amount of each such premium or discount, expressed as a percentage of that day's NAV.

click to go back to top of page

References to the “IBD® 50” in this document refer to the 50 stocks included in the IBD® 50 Index. The IBD® 50 is only the list of those 50 stocks. In contrast, the IBD® 50 Index represents a hypothetical portfolio of these 50 names included on a price-weighted basis. (Higher priced stocks represent a higher percentage of the Index compared to lower-priced stocks.) The Innovator IBD® 50 ETF will not invest in the IBD® 50 Index companies in the same proportion as reflected in the Index. The Fund is actively managed, conviction-weighted and it is not an index fund. As a result, its performance will deviate from the IBD® 50 Index.

Investing involves Risks. Principal loss is possible. Along with general market risks, an ETF that concentrates its investments in the securities of a particular industry, market, sector, or geographic area may be more volatile than a fund that invests in a broader range of industries. Additionally, the Innovator IBD® 50 ETF may invest in securities that have additional risks. Foreign companies can be more volatile, less liquid, and subject to the risk of currency fluctuations. This risk is greater for emerging markets. Small and mid-cap companies can have limited liquidity and greater volatility than large-cap companies. Also, ETFs face numerous market trading risks, including the potential lack of an active market for Fund shares, losses from trading in secondary markets, periods of high volatility and disruption in the creation/redemption process of the Fund. Unlike mutual funds, ETFs may trade at a premium or discount to their net asset value. ETFs are bought and sold at market price and not individually redeemed from the fund. Brokerage commissions will reduce returns.

The “IBD®” mark and logo have been licensed to the Adviser by Investors Business Daily, Inc. (“IBD”) for use in connection with the Fund under certain circumstances. The Fund is not sponsored, endorsed or sold by IBD. IBD makes no representation regarding the advisability of investing in the Fund. Additionally, while the Fund will generally hold all of the companies included in the IBD® 50 Index it will not invest in these companies in the same proportion as reflected in the Index. Performance will deviate from the performance of the IBD® 50 Index, and the active management of the Fund may not produce the desired results. Investor’s Business Daily® and CAN SLIM® marks and associated logos are used with permission by IBD.

Nothing on this website should be considered a solicitation to buy or an offer to sell shares of any Fund in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction.

The Fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The Statutory and Summary prospectus contains this and other important information.

Innovator Capital Management, LLC is the advisor to the Innovator IBD® 50 ETF which is distributed by Quasar Distributors, LLC